Patent Board Denies Mylan Bid For Review Of Taxoid Patent

(August 24, 2016, 12:59 PM EDT) -- ALEXANDRIA, Va. — Assertions that an Aventis Pharma S.A. patent is invalid as obvious under 35 U.S. Code Section 103 were rejected Aug. 23 by the Patent Trial and Appeal Board,...

To view the full article, register now.